Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Anlotinib
Related studies linked through entity extraction aliases.
Anlotinib in Advanced Solid Tumors With FGFR Alteration
- Status
- UNKNOWN
- Phase
- NA
Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）
- Status
- UNKNOWN
- Phase
- PHASE1
Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors
- Status
- UNKNOWN
- Phase
- PHASE1
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE3
Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients
- Status
- UNKNOWN
- Phase
- PHASE2
Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC
- Status
- UNKNOWN
- Phase
- PHASE4
Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive Chemotherapy
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC
- Status
- UNKNOWN
- Phase
- NA
Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
- Status
- UNKNOWN
- Phase
- NA
Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）
- Status
- UNKNOWN
- Phase
- PHASE4
Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029）
- Status
- COMPLETED
- Phase
- PHASE2
Anlotinib in Treatment of Recurrent Small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients
- Status
- UNKNOWN
- Phase
- PHASE2